Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

Merck discontinues TIGIT drug vibostolimab and LAG-3 drug favezelimab after Phase 3 failures with Keytruda in lung cancer and ...

Teos Therapeutics has announced that it has “deprioritised” inupadenant for the treatment of non-small cell lung cancer ...

US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...

The data include an interim look at the dose-escalation portion of a phase 2 trial assessing the adenosine A2A receptor ...

The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.

Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...